Skip Navigation


European Heart Journal Advance Access originally published online on February 4, 2005
European Heart Journal 2005 26(5):421-422; doi:10.1093/eurheartj/ehi125
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/5/421    most recent
ehi125v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Becker, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort

Richard C. Becker*

Duke Thrombosis Center, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA

* Corresponding author. E-mail address: becke021@mc.duke.edu

This editorial refers to ‘Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome. An ENTIRE-TIMI 23 substudy’{dagger} by K.K. Ray et al., on page 440

The first 10% of the full text of this article appears below.

Biomarkers may be defined as measurable cells, proteins, and/or metabolic by-products that represent, either directly or indirectly, one or more biological or pathological processes active within a defined system or disease state. In a majority of cases, biomarkers delineate variances from normal biology and either appear for the first time (newly expressed) or, more commonly according to traditional thinking, elevate beyond a normal range in response to one or more stimuli or pathologic events [e.g. cardiac specific troponin in acute myocardial infarction (MI)], rendering a clinical diagnosis; however, biomarkers may themselves participate actively in the subsequent evolution and expression of disease (e.g. C-reactive protein . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy
Kausik K. Ray, David A. Morrow, C. Michael Gibson, Sabina Murphy, Elliott M. Antman, Eugene Braunwald, and for the ENTIRE-TIMI 23 Study Group
EHJ 2005 26: 440-446. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 CirculationHome page
J. C. Gilbert, T. DeFeo-Fraulini, R. M. Hutabarat, C. J. Horvath, P. G. Merlino, H. N. Marsh, J. M. Healy, S. BouFakhreddine, T. V. Holohan, and R. G. Schaub
First-in-Human Evaluation of Anti von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers
Circulation, December 4, 2007; 116(23): 2678 - 2686.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. C. Becker
Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science
J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1777 - 1780.
[Full Text] [PDF]